Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
about
Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine TumorsPulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsManagement of patients with hepatic metastases from neuroendocrine tumorsSummary of emerging personalized medicine in neuroendocrine tumors: are we on track?Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursHigh clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors.Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaPeptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicitySomatostatin receptor based imaging and radionuclide therapy.Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy.Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy.Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.A new era for the systemic therapy of neuroendocrine tumors.Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyPeptide receptor targeting in cancer: the somatostatin paradigm.[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursPeptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicityA review of the use of somatostatin analogs in oncologyENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotateNephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy.Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy.Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrSystemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancerSynergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.Role of everolimus in pancreatic neuroendocrine tumors.
P2860
Q26783272-2CE5801A-91B6-422E-B0F0-72D008584D2CQ26996521-FE1AEDB5-2315-495B-8254-13B37BE71511Q27008832-0CF100DC-3A82-49D7-AE91-A0508704FCF2Q28078610-DAF4EFFF-1EC8-4D06-ACA4-D92E070432B1Q28247667-6A782449-57F4-44F8-9829-7FE7EE62FB92Q33435622-AD016807-14C5-483C-A133-F4298EEFD989Q33438326-CE54A1F3-0F3F-465C-A1E9-C29DD92C55ADQ33700134-F494EE39-DFA0-44C9-B8C1-4AAEB75C79FDQ34157391-72F18C4A-C71D-452C-91CB-7CCE9FB92882Q34573802-02369ACC-50FD-4E1A-9E6C-86DD881583CBQ34987688-78C39E4A-93C6-4A1B-A5E9-413846FF5C81Q35176280-9A4132BC-4B22-4A18-81B0-70BB87F1C71FQ35296661-D513B48D-0202-414E-929F-F1C871DDAD29Q35402008-BB524332-0DB1-4049-A6F1-83BB080FA13CQ35545959-CB3D8DC7-4C79-452F-B432-804FB72F20C2Q35545967-D4AE93C1-D02A-4889-9025-810633369FA8Q35675435-6A77A49F-DE31-4F47-8D17-2D7FF624326BQ35863865-5E7E7A18-A0BB-4A55-B7EF-4B6762B61643Q36021577-5ADE5AD8-18E7-4D72-8CDE-7275F5F9C19FQ36226361-59D54551-121B-4CBE-AD65-AF8EB4B2BE8CQ36578624-4C55E0DC-0A91-49B0-8392-1CF03D0BB1A4Q36638046-023EAE03-2F81-4ABD-9B3F-352BBEDACB61Q36644325-C011D1EF-AFF9-41A8-8B61-A10433379BEAQ36755905-B26D0199-468C-4518-96A2-1C3EFFA960F7Q36775316-1BA27F8D-CF00-4701-B50B-71113CC30F71Q36833161-3F54F47F-BF21-41D9-893E-570797D6EFCFQ36849357-2575068C-FB21-499D-89F5-6A7C7A7173E1Q36942728-6EB471C5-2870-449D-876B-A1D4546CE661Q37112967-00C76C47-DC33-411B-A0E1-AC57BE5D9D0FQ37143853-B97D1B55-3D67-403B-A481-927A7A4B29C1Q37167160-43D504A1-7A83-4B31-A796-722AF42F8483Q37190242-C50AFB10-9580-4403-8F2D-2B7E02FACDA3Q37201458-2A160717-1DE0-4E67-A76D-AE11D0E40243Q37350299-0FDF1B8C-1EC8-49A4-BE67-6A689F6F7F39Q37425156-CFF6854E-36B6-45C5-90B4-5B0FE04E7C41Q37594074-A5B05A4B-10A2-4037-8E21-6098CCD84783Q37607383-BAB6F2A2-6294-4716-9EE2-6FA7A2F0C6E3Q37631597-61CC6E79-BC78-49AD-8A29-AB319EA2DC37Q37698605-736B6998-7700-48BD-8019-4E27C984C286Q37935772-66FAEBFC-9913-4A07-BAAF-FBD7CB92D933
P2860
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Response, survival, and long-t ...... asized neuroendocrine cancers.
@en
Response, survival, and long-t ...... asized neuroendocrine cancers.
@nl
type
label
Response, survival, and long-t ...... asized neuroendocrine cancers.
@en
Response, survival, and long-t ...... asized neuroendocrine cancers.
@nl
prefLabel
Response, survival, and long-t ...... asized neuroendocrine cancers.
@en
Response, survival, and long-t ...... asized neuroendocrine cancers.
@nl
P2093
P356
P1476
Response, survival, and long-t ...... asized neuroendocrine cancers.
@en
P2093
Anna Imhof
Christian Schindler
Christoph Rochlitz
Helmut R Mäcke
Helmut Rasch
Jan Müller-Brand
Nicolas Marincek
Philippe Brunner
P304
P356
10.1200/JCO.2010.33.7873
P407
P577
2011-05-09T00:00:00Z